In this issue:
Sequential immunotherapy & BRAF/MEK inhibition in BRAF V600 mutation-positive melanoma
IMspire150: Atezolizumab + vemurafenib + cobimetinib in BRAF V600 mutation-positive melanoma
Tebentafusp in treatment-refractory metastatic uveal melanoma
Pembrolizumab + lenvatinib in unresectable stage III-IV melanoma
Stratifying outcomes by SN tumour deposit dimension in high-risk, SN+, AJCC stage IIIA melanoma
Immune-related AE management & survival in advanced melanoma
Genetic variation & immune-related AE risk in melanoma patients treated with ICB
Adjuvant nivolumab + ipilimumab in high-risk resected melanoma
Talimogene laherparepvec + pembrolizumab in stage IIIB-IVM1c unresectable melanoma
ONCOS-102 + pembrolizumab in advanced anti-PD-1-resistant melanoma
Please login below to download this issue (PDF)